Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
BACKGROUND
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) incidence in the United States increases with age. Given the progressive ageing of the general population, incidence of these diseases is likely to continue to rise in the future. There is an acute need for therapeutic developments because of the poor prognosis of these diseases. Since the knowledge of molecular genetics in AML and MDS has expanded recently, targeted therapeutics should offer an exciting new frontier for advancement. Of all the targeted inhibitors developed, tipifarnib represents one of the few compounds with some activity as a single agent.


METHODS
Described in this review are the molecular targets of tipifarnib, safety and tolerability of the drug, chemistry, and clinical efficacy in AML.


RESULTS
The reader will gain a thorough understanding of tipifarnib as it relates to the current and future use of the drug in AML.


CONCLUSIONS
The future of tipifarnib, along with other molecularly-targeted drugs, lies in achieving a better understanding of leukemia biology and harnessing the activity of this agent using predictive biomarkers for improved patient selection.
Epling-Burnette
Pearlie K
PK
Moffitt Cancer Center, Tampa, FL 33647, USA.
Loughran
Thomas P
TP
D000367:Age Factors; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D011379:Prognosis; D015363:Quinolones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D015363:Quinolones; D051231:Farnesyltranstransferase; C402769:tipifarnib
Leukemia. 2009 Apr;23(4):631-4
19092853
Trends Biochem Sci. 1993 Sep;18(9):349-53
8236454
Oncogene. 1997 Feb 6;14(5):623-5
9053862
Immunol Rev. 2007 Aug;218:114-25
17624948
Tumori. 1989 Aug 31;75(4):337-40
2683276
Mini Rev Med Chem. 2009 Jun;9(6):638-52
19519490
Cancer Genet Cytogenet. 2008 Jun;183(2):89-93
18503825
Blood. 2007 Jun 15;109(12):5151-6
17351110
Blood. 2003 Nov 1;102(9):3349-53
12842991
Clin Cancer Res. 2003 Oct 15;9(13):4761-71
14581347
Rev Recent Clin Trials. 2007 May;2(2):135-41
18473998
Curr Opin Investig Drugs. 2002 Feb;3(2):313-9
12020065
Hematology Am Soc Hematol Educ Program. 2002;:136-61
12446422
Blood. 2004 May 1;103(9):3271-7
14726402
J Clin Oncol. 2002 Jun 1;20(11):2726-35
12039935
Blood. 2009 Aug 6;114(6):1166-73
19470696
Cancer Control. 2003 Sep-Oct;10(5):384-7
14581893
Leukemia. 2002 Sep;16(9):1664-7
12200678
Leukemia. 2006 Apr;20(4):635-44
16467864
Br J Haematol. 2000 Dec;111(3):873-4
11122149
Eur J Haematol. 2006 Jul;77(1):51-6
16573741
Oncogene. 1997 Sep;15(11):1283-8
9315095
Leukemia. 2003 Feb;17(2):451-7
12592346
Blood. 2006 May 15;107(10):3847-53
16434492
Cancer Res. 2001 Jan 1;61(1):131-7
11196150
Blood. 2001 Jun 1;97(11):3361-9
11369625
J Biol Chem. 1995 Nov 10;270(45):26802-6
7592920
Cancer. 2003 May 1;97(9):2229-35
12712476
Leukemia. 2003 May;17(5):849-55
12750696
Leuk Lymphoma. 2001 Sep-Oct;42(5):847-53
11697639
Cell Cycle. 2005 Nov;4(11):1540-9
16205124
Leukemia. 1994 Apr;8(4):638-41
7512175
Blood. 2009 May 14;113(20):4841-52
19109557
Leuk Lymphoma. 2006 Jul;47(7):1387-91
16923573
Blood. 2000 Sep 1;96(5):1655-69
10961860
J Lipid Res. 2006 Jan;47(1):15-31
16278491
Leukemia. 1988 Aug;2(8):503-10
3166076
Biochem Soc Trans. 1996 Aug;24(3):692-9
8878828
Blood. 2008 Jul 1;112(1):45-52
18443215
Blood. 2008 Mar 1;111(5):2589-96
18160667
Clin Cancer Res. 2009 May 1;15(9):3076-83
19383813
Cancer. 2007 Apr 15;109(8):1536-42
17345612
Hum Mol Genet. 2004 May 15;13(10):1081-93
15044383
Blood. 2003 Mar 1;101(5):1692-7
12411300
Int J Cancer. 2007 Nov 15;121(10):2317-30
17657738
Blood Rev. 2003 Sep;17(3):123-9
12818222
Blood. 1993 Jul 15;82(2):590-9
8329714
Clin Cancer Res. 2008 May 15;14(10):3077-82
18483374
Cancer Res. 2009 May 1;69(9):3910-7
19383925
Nature. 1993 May 6;363(6424):85-8
8479541